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Rabies  is a viral  encephalitis,  nearly  always  fatal,  but  preventable  through  vaccines.  Rabid  animal  bite
is  the  prime  transmission  act,  while  veterinary  vaccination  is  one  of  the  best  strategies  for  rabies  gen-
eral  prevention.  Aluminum  compounds  and  saponin  are  the  commercial  adjuvants  used for  this  vaccine
nowadays.  Nevertheless,  aluminum  compounds  can  provoke  undesired  side  effects  and saponin  has  a
narrow  activity  range  without  toxicity.  B. atrophaeus  inactivated  spores  (BAIS),  with  or without  saponin,eywords:
abies
accine
acillus atrophaeus
aponin
were  then  used  as an alternative  to boost  the inactivated  rabies  virus  response.  BAIS was  as  effective  as
saponin  in augmenting  antibody  titers,  but combination  of both  adjuvants  doubled  the  titers  raised  by
them  individually.  The  combined  adjuvant  formulation  maintained  viability  for  21  months  when  stored
at  4–8 ◦C.  Overall,  BAIS  was  demonstrated  as  a viable  alternative  to  commercial  adjuvants,  while  its
combination  with  saponin  resulted  in even  higher  vaccine  potency  with  good  stability.djuvant
. Introduction
Rabies is a viral encephalitis caused by a single strand RNA
nveloped virus. This non-treatable mammal  infection has the
ighest lethality rate of all known infectious diseases [1,2]. The
ost common form of transmission is through bites from rabid
nimals [2]. Fortunately, rabies can be prevented with efﬁcacious
nactivated vaccines available for both pre and post exposure [3].
urrently, the most effective way to drastically decrease the infec-
ion rates is through veterinary vaccination [2]. The rabies vaccines
or animals are administered by parenteral or oral route, with
nactivated or attenuated rabies virus, and may  contain aluminum
ompounds and saponin as adjuvants. Independent of the vaccine
ype used, animals have to be vaccinated several times during their
ifetime (1–3 years intervals) [1], an expensive and not always exe-
uted practice.
Saponin is currently a licensed adjuvant for veterinary rabies
accines. Its adjuvant mechanism is not fully understood, but
esults in strong immunomodulation [4]. However, the narrow
oncentration range that presents immunomodulation without
oxicity limits its individual application [5].
Experimentally, a large sort of techniques have been applied
o improve veterinary rabies vaccine, including new adjuvants
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[6,7]. This work proposes another innovative approach directed to
vaccine improvement, combining Bacillus atrophaeus inactivated
spores (BAIS) and saponin with rabies inactivated virus.
The  non-pathogenic strain B. atrophaeus ATCC 9372 was origi-
nally classiﬁed as Bacillus subtilis, but the production of a pigment
under certain culture conditions, absent in B. subtilis subspecies,
led to the reclassiﬁcation. Notwithstanding, except for pigment
production, both species are indistinguishable by standard char-
acterization methods [8]. Recently, B. subtilis inactivated spores
(BSIS) were presented as an effective microparticle adjuvant. The
approach was  effective for induction of higher IgG titers against
tetanus toxoid than the titers induced by the toxoid alone [9]. Live
or inactivated spores were both capable of inducing an effective
cellular and humoral immune response against the tested antigens
[10]. The successful application of BSIS as a vaccine adjuvant stimu-
lated the use of the highly similar strain B. atrophaeus as an adjuvant
candidate for rabies veterinary vaccine.
2. Methods
2.1. Reference materials and reagents
The second International Standard for Human Rabies
Open access under the Elsevier OA license.Immunoglobulin determined by the World Health Organiza-
tion (WHO 2nd HRIG), containing 30 international units/mL
(IU/mL), was obtained from the National Institute for Biological
Standards and Control (NIBSC, United Kingdom). In vitro detection
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f Rabies virus by immunoﬂuorescence was performed with
uorescein labeled anti-rabies nucleocapsid conjugate (Bio-rad,
SA). Saponin adjuvant extracted from Quillaja saponaria (QSA®)
as donated by Beraca, Brazil.
.2. Inactivated B. atrophaeus spores (BAIS)
B. athrophaeus ATCC 9372 was grown and sporulated as previ-
usly published [11]. Brieﬂy, vegetative cells were sporulated for
 days/37 ◦C in Plate Count Agar (PCA) medium, supplemented with
.1% soluble starch, 0.05% magnesium sulfate, 0.05% manganese
ulfate and 0.05% calcium chloride. Spores were then harvested
nd suspended in 0.02 M calcium acetate solution (pH 9.7). After
entrifugation (2000 × g/30 min), four successive washes were per-
ormed with 0.02 M calcium acetate solution (pH 9.7). The spores
ere inactivated by autoclavation (121 ◦C, 20 min), centrifuged
2000 × g/30 min), washed and resuspended in phosphate buffer
PBS pH 7.2). The concentration of the suspension was adjusted to
 × 108 spores/mL. Quantiﬁcation of viable spores was done before
nd after autoclavation, by plating and incubating spores aliquots
erially diluted in TSA (37 ◦C/48 h), followed by counting of colony-
orming units. In order to assure inactivation after autoclavation,
he incubation period was extended to 7 days, with daily monitor-
ng. The spores were considered inactivated when no colonies were
bserved, independent of the dilution used.
.3. Rabies virus
The  inactivated rabies virus used for vaccination was  rabies ﬁxed
V Pasteur virus (Pasteur Institute, France), adapted and extracted
rom BHK-21 cells (C13 – ATCC CCL-10) as published before [12]
nd quantiﬁed by Antigen Binding Test (ABT) [13]. The stock solu-
ion contained 8 IU/mL and 1 mg/mL  protein content. Challenge
irus strain used was CVS-11 (Pasteur Institute, France), which was
roduced in BHK-21 cells and provided by Instituto Nacional de
ontrole de Qualidade em Saúde (INCQS, Brazil).
.4. Determination of antigen adsorption by inactivated spores
Log  serial dilutions of inactivated spores suspension in PBS pH
.2 were mixed with rabies inactivated virus (1 mg/mL  protein con-
ent), incubated (2 h/4 ◦C) and centrifuged (2000 × g/30 min). The
upernatant containing the non-adsorbed virus was collected and
ssayed for protein content by Bicinchoninic Acid Assay Kit (Merck,
SA).
.5. Determination of rabies cell culture infective dose 50%
CCID50%)
Rabies  CVS titration was done to calculate the CCID50. Eight
liquots of stock CVS were serially diluted (log-dilution). BHK21
ells diluted in Eagle’s Minimum Essential Medium (EMEM) and
.5% fetal bovine serum were added to each well and incubated
vernight. Cells were then washed and ﬁxed with cold acetone,
ried at room temperature and stained with FITC anti-rabies anti-
ody. Plates were analyzed on an inverted ﬂuorescence microscope
8 ﬁelds per well) at 200× magniﬁcation. Each analyzed ﬁeld was
lassiﬁed as positive (virus infection) or negative, based on ﬂuores-
ence spots. Calculation of CCID50% was done according to Reed
nd Muench method [14]..6.  Immunization and blood collection
The animal work described here was in accordance with the
nimal care procedures described in NIH OACU-ARAC guidelines,cine 30 (2012) 3351– 3354
and  approved by the Institutional Animal Care and Use  Commit-
tee from Butantan Institute (protocol 69/2007). Five-week-old male
Swiss mice were obtained from Butantan Institute (SP, Brazil). Six
test groups of 8 mice each were inoculated by the intraperitonial
route (27 G × ½′′ needle) with 0.5 mL  of the following preparations:
Group 1 with saline phosphate buffer pH 7.2 (negative control
group); group 2 with inactivated rabies virus (1 IU/dose); group
3 with BAIS (106 spores/dose); group 4 with inactivated rabies
virus (1 IU/dose) and BAIS (106 spores/dose); group 5 with inac-
tivated rabies virus (1 IU/dose), QSA (70 g/dose) and group 6 with
inactivated rabies virus (1 IU/dose), BAIS (106 spores/dose), QSA
(70 g/dose). Two additional groups were inoculated, one with
108 spores/dose and another with 1010 spores/dose, for toxicity
evaluation. Mice were inoculated two times (days 0 and 14) and
blood collected by submandibular vein (4 mm lancet) on day 21. For
stability purposes, 3 batches of the formulation containing inacti-
vated rabies virus, BAIS and QSA were manufactured and stored at
4–8 ◦C. A group of eight mice to each batch in each evaluation time
point were immunized and blood collected as described above.
2.7.  Blood processing and antibody analysis
Blood samples were incubated for 1 h at room temperature and
centrifuged for 20 min/1500 × g/4 ◦C. The supernatant (serum) col-
lected was analyzed by ELISA to determine anti-rabies glycoprotein
antibody titers using Platelia Rabies II kit (Bio-Rad) [15]. Sample
serum was  also heat-inactivated (56 ◦C for 30 min) and analyzed
through RFFIT, as described before [12], to determine anti-rabies
neutralizing antibody titers. RFFIT is listed by the European Phar-
macopeia as one of the methods for potency evaluation of rabies
veterinary vaccines [16]. Triplicates of sample serum and WHO  2nd
HRIG (standard) were serially diluted in 96 well plates. CVS virus
was then distributed to all wells (200 × CCID50), except negative
control wells, and the plate incubated for 90 min/37 ◦C/5% CO2.
After incubation, BHK21 cells diluted in Eagle’s Minimum Essential
Medium (EMEM) and 2.5% fetal bovine serum were added to each
well and incubated overnight. Cells were then washed and ﬁxed
with cold acetone, dried at room temperature and stained with FITC
anti-rabies antibody. Plates were analyzed with an inverted ﬂuo-
rescence microscope (8 ﬁelds per well) at 200× magniﬁcation. Each
analyzed ﬁeld was  classiﬁed as positive (virus infection) or nega-
tive (virus neutralization) based on ﬂuorescence spots. The serum
dilution that reduces the number of ﬁelds containing infected cells
by 50% (ED50) was  calculated using the same method applied to
CCID50%. Antibody neutralizing titers were calculated based on
ED50 from the standard serum, expressed as International Units
per milliliter (IU/mL).
2.8.  Statistical analysis
Signiﬁcant  statistical differences between group means were
analyzed by Student’s t test (  ˛ = 0.05, two  tailed).
3. Results and discussion
3.1.  Toxicity evaluation of inoculated mice
Toxicity was  evaluated on a daily basis through the following
parameters: physiological changes (signiﬁcant weight gain or loss,
diarrhea), behavioral changes (fatigue, hyperactivity) or physical
changes (hair loss, excessive local inﬂammation). The monitoring
process was followed until 21 days after the second inoculation.The mice groups inoculated with 1 × 106, 1 × 108 or 1 × 1010
inactivated spores/dose presented no apparent signs of toxicity.
The highest dose tested was  10,000 times higher than the dose used
in the putative rabies vaccine.
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Fig. 1. Evaluation of antigen adsorption by BAIS. Serial log dilution of BAIS were
mixed  with stock solution of rabies inactivated virus (8 UI/mL, 1 mg/mL  protein
content),  centrifuged and the supernatant was tested for protein content. The
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Fig. 2. Potency evaluation of putative formulations for inactivated rabies vaccine.
Groups  of eight Swiss mice were inoculated by the intraperitoneal route (days 0
and 14) with inactivated rabies virus, saponin, BAIS or combinations of this com-
ponents. Each column represents the mean serum potency value obtained from
each test group (day 21), assayed two times in triplicate. White columns stand for
potency values obtained through RFFIT and quadriculated columns through ELISA.
Standard deviation of each mean is represented by the error bars in the respective
column. Serum from mice inoculated solely with saline solution or adjuvant did not
have detectable antirabies potency and therefore were not represented graphically.
Statistical  T test was applied to compare intra assay difference of means. Aster-
isks  refer to differences between the VRI group mean and the other groups with
antigen. **p < 0.01, ***p < 0.001; p values for RFFIT: VRI and VRI + saponin = 0.0011,
VRI  and VRI + BAIS = 0.0077, VRI and VRI + BAIS + saponin = 0.0003, VRI + saponinoncentration  1 ×1010 BAIS was also tested, but no protein was detected. Values
epresented  in the graph are the mean of three independent experiments with error
ars for standard deviation.
Saponin toxicity in Swiss mice was evaluated by our group
efore [5]. The highest saponin concentration without intoxication
igns was found to be 90 g/dose. As a safety precaution, we  used
0 g/dose in the following experiments.
The same toxicity parameters were monitored for all immunized
roups, however no signs of toxicity or abnormal local reactions
ere observed. Although no symptoms were detectable, toxicity of
he chosen vaccine formulation should further be studied in depth
o conﬁrm safety for future application.
.2. BAIS ability to adsorb antigens
The spores of BSIS were reported as particles able to adsorb anti-
ens [10]. In order to verify if BAIS could have the same property,
he adsorption ability of BAIS was tested with the stock solution
f rabies inactivated virus (Fig. 1). BAIS were mixed with antigen,
entrifuged and the supernatant was tested for protein content. The
upernatant of centrifuged BAIS alone presented no detectable pro-
ein content. The centrifuged antigen alone had 1 mg/mL  of protein
ontent. When serial log dilutions of BAIS were mixed with the inac-
ivated virus, a linear correlation between log dilution and protein
ontent from the supernatant were observed (Fig. 1). The inversed
orrelation exists within a large concentration range (1 × 103 to
 × 109 BAIS), in which the decrease of supernatant protein con-
ent means an increase of protein adsorption on spores. BAIS at
 × 1010 was enough for full antigen adsorption, as no protein con-
ent was detected in the supernatant. The number of spores used
or immunization experiments (1 × 106 BAIS) was able to absorb
.5 mg  of antigen. Since the protein content used for antigen inoc-
lation was 0.125 mg  (1 UI/dose), the quantity of spores should be
nough to absorb the amount of antigen in the suspension. This
ssumption was conﬁrmed by protein analysis, in which no protein
as detected.
.3.  Potency evaluation of putative formulations for inactivated
abies  vaccine
Putative rabies vaccines were prepared with or without saponin
nd BAIS as adjuvants, while inactivated rabies virus was uti-
ized as the source of antigens. In order to determine anti-rabies
otency increments due to adjuvant action, outbred mice were
noculated with the formulations and their serum assayed for rabiesand  VRI + BAIS = 0.0512; p values for ELISA: VRI and VRI + saponin = 0.0097. VRI
and VRI + BAIS = 0.0032. VRI and VRI+ BAIS + saponin < 0.0001, VRI + saponin and
VRI + BAIS = 0.0910.
neutralizing antibodies (Fig. 2). The serum was also analyzed by
enzyme-linked immunosorbent assay (ELISA) to conﬁrm the results
obtained by the traditional in vitro screening process (Fig. 2). The
data from both methods were correlated, as expected [15]. Signiﬁ-
cant higher titers of antibodies were induced when an adjuvant was
inoculated, as compared with the inactivated virus alone (p < 0.01).
Nonetheless, the antibody titers from mice immunized with anti-
gen and saponin did not differ from the titers obtained from
mice inoculated with antigen and BAIS. When saponin and BAIS
were combined with inactivated rabies virus in the same inocula-
tion, anti-rabies glycoprotein antibody and neutralization antibody
titers quadruplicated at least (p < 0.001). The exact p values for
each comparison are listed in Fig. 2 legend. The improvement
achieved shows that although inactivated spores were as effective
as saponin, adjuvant combination was  even more. Saponin alone
could have led to higher antibody titers if it was used more con-
centrated, but this strategy would have resulted in toxicity as an
undesired side effect [5]. A preliminary screening experiment per-
formed by our group showed no gain in adjuvant activity by raising
the amount of spores per dose (data not shown). The signiﬁcant
higher potency showed when both adjuvants were combined led
us to choose this formula for stability evaluation.
3.4. Stability evaluation
The  next step consisted in determining stability of the formula-
tion containing both adjuvants to access its suitability. According
to WHO, potency is a stability indicating parameter to measure
alterations on the efﬁcacy of a vaccine during a timeline [17]. The
stability evaluation was based on potency determination by RFFIT
from 3 independent batches, analyzed every trimester from days
10 to 820 after batch manufacturing (Fig. 3). The potency decreased
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[nd stored at 4–8 ◦C. Serum potency (RFFIT) of groups of eight immunized Swiss m
atch manufacturing. Values represented in the graph are the mean of the three ba
rogressively, but the ﬁrst 50% loss occurred in a longer period than
he loss of the remaining potency. The seventh trimester was  the
ast one in which all batches retained potency values above the min-
mum required for vaccine commercialization (1 IU/mL) [16], hence
he shelf life of this formulation can be stated as 21 months. Addi-
ional stability parameters were evaluated: visual stability (color
hange, turbidity or precipitation) and pH monitoring. None of the
ited parameters changed over the analyzed period.
.  Conclusion
This work demonstrates that BAIS can absorb inactivated rabies
irus and improve murine antibody titers raised by this antigen. In
ddition to this fact, the spores did not provoke any visual intoxica-
ion signs. The commercial saponin admixed with the experimental
djuvant BAIS resulted in excellent vaccine potency, superior to the
esults obtained with a single adjuvant. The formulation was  viable
or 21 months at 4–8 ◦C, while most commercial veterinary vac-
ines have a shelf life of 12 months. Additional studies are needed
o conﬁrm the safety of this formulation containing two adju-
ants. Further studies with different animal species can conﬁrm the
roadness of efﬁcacy for this putative vaccine and future practical
pplication.
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